Provided by Tiger Fintech (Singapore) Pte. Ltd.

Pacific Biosciences of California

1.49
-0.0500-3.25%
Pre-market: 1.47-0.0200-1.34%06:54 EDT
Volume:5.67M
Turnover:8.71M
Market Cap:447.13M
PE:-0.64
High:1.60
Open:1.55
Low:1.46
Close:1.54
Loading ...

Is Pacific Biosciences of California (NASDAQ:PACB) A Risky Investment?

Simply Wall St.
·
29 Jul

PacBio HiFi sequencing used to power first Arab human pangenome

TIPRANKS
·
24 Jul

PacBio joins 1000 Genomes Long Read project to add isoform sequencing

TIPRANKS
·
23 Jul

PacBio Joins the 1000 Genomes Long Read Project to Add Isoform Sequencing with Kinnex and Revio

GlobeNewswire
·
23 Jul

QIAGEN NV Expands NGS Portfolio with Launch of QIAseq xHYB Long Read Panels for Enhanced Genomic Research

Reuters
·
23 Jul

PacBio to Report Second Quarter 2025 Financial Results on August 7, 2025

GlobeNewswire
·
22 Jul

Here's Why You Should Add PacBio Stock to Your Portfolio Now

Zacks
·
09 Jul

Pacific Biosciences Is Maintained at Equal-Weight by Barclays

Dow Jones
·
25 Jun

Pacific Biosciences (PACB) Receives a Hold from Barclays

TIPRANKS
·
25 Jun

Pacific Biosciences of California Inc. Conducted Annual Meeting

Reuters
·
07 Jun

PacBio partners with Target ALS to launch genome sequencing initiative

TIPRANKS
·
02 Jun

Largest borrow rate increases among liquid names

TIPRANKS
·
28 May

BRIEF-PacBio Expands Distribution in China, Gaining Access to New Clinical Lab Networks via Haorui Gene

Reuters
·
22 May

PacBio appoints Haorui Gene as official distributor in China

TIPRANKS
·
22 May

Michele Farmer, Officer, Reports Disposal of Common Shares in Pacific Biosciences of California Inc

Reuters
·
22 May

Pacific Biosciences Is Maintained at Neutral by Piper Sandler

Dow Jones
·
16 May

Pacific Biosciences Price Target Maintained With a $1.80/Share by Stephens & Co.

Dow Jones
·
15 May

PacBio board: Independent investigation concludes allegations unsubstantiated

TIPRANKS
·
12 May

Piper Sandler Sticks to Its Hold Rating for Pacific Biosciences (PACB)

TIPRANKS
·
09 May

Pacific Biosciences of California Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
09 May